Exosome Diagnostics and Therapeutics Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Exosome Diagnostics and Therapeutics Market

Exosome Diagnostics and Therapeutics Market Size, Share & Trends by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032

FREE BROCHURE FREE SAMPLE REPORT
Report Code: BT 9039 Jun, 2024, by marketsandmarkets.com

Exosome Diagnostics and Therapeutics Market Size, Share & Trends

The size of global exosome diagnostics and therapeutics market is projected to grow from USD 59 million in 2024 to USD 2,347 million by 2029 at a CAGR of 108.9%. However, the candidates for exosome-based therapeutics are expected to be launched in the market from 2029 onwards. Thus, exosome diagnostics and therapeutics market in terms of revenue was estimated to be worth $59 million in 2024 and is poised to reach $6,848 million by 2032, growing at a CAGR of 81.2% from 2024 to 2032. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

The growth of this market is driven by factors such as the increasing collaborations & commercialization initiatives, emerging potential of exosome-based liquid biopsy, and growing outsourcing of exosome manufacturing activities. However, inadequate protocols for exosome development & production may pose a challenge to the market growth.

Exosome Diagnostics and Therapeutics Market Trends

Exosome Diagnostics and Therapeutics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Exosome Diagnostics and Therapeutics Market

Exosome Diagnostics And Therapeutics Market Dynamics

DRIVER: Increasing initiatives for product commercialization

Despite the robust product development initiatives by market players, commercialization of both exosome-based diagnostics and therapeutics is slow-paced. This has led to a spike in strategic collaborations to expedite commercial market opportunities. Companies operating in the exosome diagnostics market aim to capitalize on the growing opportunities in this dynamic industry and overcome the challenges associated with developing & commercializing exosome-based diagnostic technologies. In comparison, companies operating in therapeutics collaborate to leverage proprietary advanced exosome technologies, including exosome isolation, characterization, and analysis, to ensure the rapid launch of therapeutic candidates in the market. In March 2024, BIONET (China), a prominent player in Taiwan’s regenerative medicine sector, collaborated with UNIVERCELLS TECHNOLOGIES (Belgium) to integrate the latter’s scale-X fixed-bed bioreactor. By leveraging the scale-X hydro system, BIONET aims to optimize the production of extracellular vesicles (including exosomes) generated by MSCs for therapeutic applications. This development signifies a potential advancement in the large-scale manufacturing of standardized exosome-based therapies.

RESTRAINT: Technical complexities associated with exosome isolation

The complexities associated with isolating and characterizing exosomes, along with existing technological limitations, are significant impediments to the progress of exosome research. These challenges hinder the development of robust methodologies and impact the overall advancement of the field. The complications involved in working with exosomes, which are small extracellular vesicles, pose difficulties in their isolation and thorough characterization. Technological limitations further exacerbate these challenges, preventing achieving precise and consistent results.

OPPORTUNITY: Growing adoption of exosome biomarkers for personalized medicine

Over the years, the popularity of personalized medicine has increased due to limitations of standard diagnosis and treatment. Different fields of medicine, from cancer to psychiatry, are heading towards tailored treatments for each patient based on their biological & clinical characteristics. In 2022, the FDA approved 12 personalized medicines, representing approximately 34% of all newly approved therapeutic molecular entities. Also, five new gene or cell-based therapies were approved. Additionally, in 2022, the FDA expanded the indications for several personalized therapies, showing increased research in personalized medicines backed by increased investments, supporting the growth opportunities of the exosome research space.

CHALLENGE: Inadequate protocols for exosome development & production

The exosome field is still nascent, and no gold standards have been developed. The diversity of exosome isolation techniques, including ultracentrifugation, precipitation, and chromatography, lacks a universally agreed-upon methodology, resulting in variations in purity, yield, and contamination levels. Standardizing parameters for exosome characterization, such as size distribution, surface markers, and cargo content, is complicated by the inherent heterogeneity within exosome populations. The prevalent method, differential centrifugation, often relies on factors such as sample viscosity, resulting in inconsistent exosome capture. Alternative approaches, including size-exclusion chromatography and immunoaffinity capture, though presenting certain benefits, encounter limitations in accuracy and specificity.

EXOSOME DIAGNOSTICS AND THERAPEUTICS: INDUSTRY ECOSYSTEM

Based on the current scenario of commercializing exosomes, concerning diagnostics and therapeutics, the exosome value chain includes four integral steps. These are research & development; raw material procurement & manufacturing; regulatory compliance and quality assurance (QA); and marketing, sales, and distribution. Within this value chain, cell souring, exosome generation/development, exosome engineering, exosome cargo loading, and exosome formulation are critical steps in commercializing exosomes. The supply chain for exosome therapies spans the entire process of sourcing materials to distribute the final product to healthcare providers (hospitals, clinics/physician settings) or patients. Based on the complexity of exosome manufacturing and the need for stringent quality control, establishing a robust supply chain is essential for ensuring the safety, efficacy, and scalability of exosome therapies.

The prominent players in the global exosome diagnostics and therapeutics market are Bio-Techne (US), NanoFCM Inc. (UK), System Biosciences, LLC. (US), Capital Biosciences, Inc. (US), AMSBIO (UK), INOVIQ (Australia), Direct Biologics LLC (US), Regeneus Ltd (Australia), CUREXSYS (Germany), Aegle Therapeutics (US), Mercy Bioanalytics (US), multimmune GmbH (Germany), RION (US), Exogenus Therapeutics (Portugal), Everzom (France), Kimera Labs (US) NanoSomiX, Inc. (US), Exonox Biosciences, Inc. (Taiwan), Capricor Therapeutics, Inc. (US), Evox Therapeutics (US), and ILIAS Biologics Inc. (Korea).

Ecosystem Analysis: Exosome Diagnostics and Therapeutics Market

Exosome Diagnostics and Therapeutics Market Ecosystem

Source: Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis

The exosome therapeutics segment is expected to gain traction post of the exosome diagnostics and therapeutics industry 2029.

The market is segmented based on type into exosome diagnostics and exosome therapeutics. Exosome therapeutics have emerged as an attractive market space, with increasing candidates entering clinical trials. The current pipeline indicates that 30 candidates are under development, with a majority (~41%) in Phase 1/Early Phase 1. The Asia Pacific region is at the forefront of therapeutics, with over 40% of exosome therapeutic candidates in the clinical pipeline. Meanwhile, North America and Europe comprise 46% of the therapeutics pipeline. The Middle East represents the remaining 10-12% of the pipeline, with the applicants belonging to Israel.

The exosome kits & reagents segment is anticipated to dominate the exosome diagnostics and therapeutics industry through 2024-2032.

Based on product & service, the market is segmented into instruments & services and kits & reagents. Exosome kits and reagents simplify exosome isolation, identification, measurement, and characterization. The commercial kits in this segment include those for Exolution RNA, Exolution Plus, ExoEasy, and ExoDx (Bio-Techne); XCF Liquid Biopsy Ki and ExoELISA ULTRA (System Biosciences); SubX-Exo Kit (Capital Biosciences); and ExoGAG (AMSBIO). These kits aim to achieve the optimal extraction of exosomes from a wide range of biological samples while maintaining functionality and integrity efficiently.

The blood & blood plasma source segment of the exosome diagnostics and therapeutics industry is anticipated to grow at the fastest pace throughout the forecast period.

Based on source, the market is segmented into stem cells, blood & blood plasma, urine, and other samples (saliva and endothelial cells). Blood plasma-derived exosomes are being investigated as potential diagnostic biomarkers for several conditions, including cancer, cardiovascular diseases, neurodegenerative disorders, infectious diseases, and inflammatory conditions. The cargo of exosomes, particularly their nucleic acids and proteins, can reflect disease-specific changes in gene expression, signaling pathways, and cellular processes, offering valuable insights into disease diagnosis, prognosis, and treatment response.

Clinics and physician settings segment generated the highest revenue in 2024 in the exosome diagnostics and therapeutics industry.

Hospitals and clinics & physician settings are the key end users of exosome products. The distribution of exosome-based tests is expected to be influenced by establishing clinics and physician settings. The exosome diagnostics market heavily relies on clinics and physician settings to distribute products. Commercialized exosome separation, characterization, and at-home test kits are used or marketed through clinics and physician settings. The rising demand for liquid biopsy kits in this end-user segment is expected to drive the market growth. Clinical testing laboratories use data from exosome-based liquid biopsy kits to help expedite the development & approval of exosome-based diagnostic tests.

The North America exosome diagnostics and therapeutics market is expected to dominate the exosome diagnostics and therapeutics industry.

The global exosome diagnostics and therapeutics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. In 2023, North America (US and Canada) dominated the market being a sole a revenue contributor of revenue in 2023. The large share of North America is attributed to the product approval of the only commercial exosome-based test for prostate cancer offered by Bio-Techne (US). Other factors that support the growth of the market include significant investments in R&D for the development of exosome diagnostics and therapeutics, a favorable environment for market players, and a strong regulatory framework.

Exosome Diagnostics and Therapeutics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The global exosome diagnostics and therapeutics market is monopolized, with commercial products approved only in the diagnostics market space. This has created a monopoly in the market, with Bio-Techne (US) being the only player currently offering commercial exosome-based tests. The ExoDx prostate cancer test is a key product offered by Bio-Techne. Companies mapped in the report include NanoFCM Inc. (UK), System Biosciences, LLC. (US), Capital Biosciences, Inc. (US), AMSBIO (UK), INOVIQ (Australia), Direct Biologics LLC (US), Regeneus Ltd (Australia), CUREXSYS (Germany), Aegle Therapeutics (US), Mercy Bioanalytics (US), multimmune GmbH (Germany), RION (US), Exogenus Therapeutics (Portugal), Everzom (France), Kimera Labs (US), NanoSomiX, Inc. (US), Exonox Biosciences, Inc. (Taiwan), Capricor Therapeutics, Inc. (US), Evox Therapeutics (US), and ILIAS Biologics Inc. (Korea).

Scope of the Healthcare IT Industry

Report Metric

Details

Market Revenue in 2024

$59 million

Projected Revenue by 2032

$6,848 million

Revenue Rate

Poised to Grow at a CAGR of 81.2%

Market Driver

Increasing initiatives for product commercialization

Market Opportunity

Growing adoption of exosome biomarkers for personalized medicine

This research report categorizes the exosome diagnostics and therapeutics market to forecast revenue and analyze trends in each of the following submarkets:

By Type
  • Exosome Diagnostics
  • Exosome Therapeutics
By Product & Service
  • Instruments & Services
  • Kits & Reagents
By Source
  • Stem Cells
  • Blood & Blood Plasma
  • Urine
  • Other Sources
By Application
  • Cancer
  • Dermatological Diseases
  • Musculoskeletal Disorders
  • Cardiovascular Diseases
  • Other Application
By End User
  • Hospitals
  • Clinics and Physician Settings
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • China
    • South Korea
    • Australia
    • India
    • Japan
    • RoAPAC
  • Rest of the World

Recent Developments of the Exosome Diagnostics And Therapeutics Industry:

  • In September 2023, INOVIQ entered into a license and supply agreement with ResearchDx for INOVIQ’s EXO-NET exosome capture technology. Through this agreement, ResearchDx incorporated EXO-NET technology in its portfolio of exosome diagnostic services.
  • In April 2022, INOVIQ expanded its collaboration with the University of Queensland (UQ) for the co-development of exosome-based ovarian cancer screening tests. Through the development, INOVIQ has exclusive rights to license and commercialize this exosome-based early-detection test for ovarian cancer.
  • In March 2021, Exosome Diagnostics revealed that its ExoDx Prostate test (EPI) kit completed clinical validation, enabling self-certification as CE-IVD.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 27)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 MARKET SEGMENTATION
           1.3.2 REGIONS COVERED
                    FIGURE 2 REGIONAL SEGMENTATION
           1.3.3 YEARS CONSIDERED
           1.3.4 CURRENCY CONSIDERED
    1.4 STAKEHOLDERS 
    1.5 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 31)
    2.1 RESEARCH DATA 
          FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 4 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
          FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS 
          FIGURE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
          FIGURE 9 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.4 DATA TRIANGULATION AND MARKET BREAKDOWN 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ASSESSMENT ANALYSIS 
          TABLE 1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: RISK IMPACT ANALYSIS
    2.7 RECESSION IMPACT ANALYSIS 
          TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
          TABLE 3 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 4 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)

3 EXECUTIVE SUMMARY (Page No. - 42)
    FIGURE 11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION)
    FIGURE 12 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY PRODUCT & SERVICE, 2029 VS. 2032 (USD MILLION)
    FIGURE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2029 VS. 2032 (USD MILLION)
    FIGURE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY APPLICATION, 2029 VS. 2032 (USD MILLION)
    FIGURE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2029 VS. 2032 (USD MILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET
 
4 PREMIUM INSIGHTS (Page No. - 47)
    4.1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET OVERVIEW 
          FIGURE 17 EMERGING POTENTIAL OF EXOSOME-BASED LIQUID BIOPSY TO DRIVE MARKET
    4.2 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE AND COUNTRY (2029) 
          FIGURE 18 EXOSOME THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2029
    4.3 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION) 
          FIGURE 19 EXOSOME DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 49)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 20 EXOSOME DIAGNOSTICS AND THERAPEUTIC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Emerging potential of exosome-based liquid biopsy
                    5.2.1.2 Increasing initiatives for product commercialization
                    5.2.1.3 Growing outsourcing of exosome-based manufacturing activities
           5.2.2 RESTRAINTS
                    5.2.2.1 Technical complexities associated with exosome isolation
                    5.2.2.2 Stringent regulatory requirements
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing adoption of exosome biomarkers for personalized medicine
           5.2.4 CHALLENGES
                    5.2.4.1 Inadequate protocols for exosome development & production
    5.3 SUPPLY CHAIN ANALYSIS 
          FIGURE 21 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 22 VALUE CHAIN ANALYSIS: MANUFACTURING PROCESSES AND REGULATORY INVESTMENTS ADD MAXIMUM VALUE
    5.5 PATENT ANALYSIS 
           5.5.1 PATENT ANALYSIS: EXOSOME DIAGNOSTICS
                    FIGURE 23 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, JANUARY 2013–OCTOBER 2023
                    FIGURE 24 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, BY JURISDICTION
           5.5.2 PATENT ANALYSIS: EXOSOME THERAPEUTICS
                    FIGURE 25 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, JANUARY 2013–OCTOBER 2023
                    FIGURE 26 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, BY JURISDICTION
    5.6 REGULATORY LANDSCAPE 
           5.6.1 REGULATORY SCENARIO
                    5.6.1.1 North America
                               5.6.1.1.1 US
                               5.6.1.1.2 Canada
                    5.6.1.2 Europe
                               5.6.1.2.1 Germany
                               5.6.1.2.2 Spain
                    5.6.1.3 Asia Pacific
                               5.6.1.3.1 China
                               5.6.1.3.2 Japan
                               5.6.1.3.3 South Korea
           5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 6 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.7 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 7 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.7.1 THREAT OF NEW ENTRANTS
           5.7.2 THREAT OF SUBSTITUTES
           5.7.3 BARGAINING POWER OF SUPPLIERS
           5.7.4 BARGAINING POWER OF BUYERS
           5.7.5 INTENSITY OF COMPETITIVE RIVALRY
    5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EXOSOME DIAGNOSTICS & THERAPEUTICS
           5.8.2 BUYING CRITERIA FOR END USERS
                    FIGURE 28 KEY BUYING CRITERIA FOR END USERS
    5.9 INVESTMENT AND FUNDING SCENARIO 
          TABLE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: INVESTMENT & FUNDING SCENARIO
    5.10 EXOSOME THERAPEUTICS: DEVELOPMENT & MANUFACTURING PROCESS 
           5.10.1 EXOSOME ISOLATION
                     TABLE 9 EXOSOME ISOLATION TECHNIQUES
           5.10.2 EXOSOME CHARACTERIZATION AND QC
           5.10.3 EXOSOME PRODUCTION
    5.11 PIPELINE ANALYSIS 
           FIGURE 29 EXOSOME PIPELINE, BY INTERVENTION TYPE
           FIGURE 30 EXOSOME PIPELINE, BY PHASE
           5.11.1 PIPELINE ANALYSIS: EXOSOME THERAPEUTICS
                     FIGURE 31 EXOSOME THERAPEUTICS PIPELINE, BY PHASE
                     FIGURE 32 EXOSOME THERAPEUTICS PIPELINE, BY REGION
           5.11.2 PIPELINE ANALYSIS: EXOSOME DIAGNOSTICS
                     FIGURE 33 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY APPLICATION
                     FIGURE 34 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY COUNTRY
                     TABLE 10 PIPELINE PRODUCTS FOR EXOSOME DIAGNOSTICS
                     TABLE 11 PIPELINE PRODUCTS FOR EXOSOME THERAPEUTICS
    5.12 PRICING ANALYSIS 
           5.12.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
                     TABLE 12 AVERAGE SELLING PRICE OF EXOSOME DIAGNOSTIC PRODUCTS, BY KEY PLAYER
           5.12.2 AVERAGE SELLING PRICE TREND, BY REGION
    5.13 ECOSYSTEM ANALYSIS 
           FIGURE 35 EXOSOME DIAGNOSTICS AND THERAPEUTICS: ECOSYSTEM MAP
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           FIGURE 36 REVENUE SHIFT AND NEW POCKETS
    5.15 KEY CONFERENCES & EVENTS 
           TABLE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2024–2025)
    5.16 TECHNOLOGY ANALYSIS 
           5.16.1 KEY TECHNOLOGIES
                     TABLE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: KEY TECHNOLOGIES
           5.16.2 COMPLIMENTARY TECHNOLOGIES
           5.16.3 ADJACENT TECHNOLOGIES
 
6 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE (Page No. - 90)
    6.1 INTRODUCTION 
          TABLE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 16 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
    6.2 EXOSOME DIAGNOSTICS 
           6.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION & DIAGNOSIS TO PROPEL MARKET
                    TABLE 17 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 18 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 19 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 20 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 21 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 22 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 23 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 24 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
    6.3 EXOSOME THERAPEUTICS 
           6.3.1 INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH
                    TABLE 25 EXOSOME THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 26 EXOSOME THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 27 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 28 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 29 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 30 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 31 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 32 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
 
7 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 98)
    7.1 INTRODUCTION 
          TABLE 33 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
          TABLE 34 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2030–2032 (USD MILLION)
    7.2 KITS & REAGENTS 
           7.2.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTIC KITS TO DRIVE MARKET
                    TABLE 35 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 36 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 38 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 39 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 40 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 41 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 42 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
    7.3 INSTRUMENTS & SERVICES 
           7.3.1 RISING FOCUS ON OUTSOURCING EXOSOME PREPARATION ACTIVITIES TO SUPPORT MARKET GROWTH
                    TABLE 43 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 44 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2030–2032 (USD MILLION)
 
8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE (Page No. - 104)
    8.1 INTRODUCTION 
          TABLE 45 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
          TABLE 46 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
    8.2 STEM CELLS 
           8.2.1 GROWING UPTAKE OF MSC-DERIVED EXOSOMES IN CELLULAR PROCESSES TO DRIVE MARKET
                    TABLE 47 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 48 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 49 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 50 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 51 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 52 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 53 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 54 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
    8.3 BLOOD & BLOOD PLASMA 
           8.3.1 ABILITY TO ENHANCE TREATMENT RESPONSE AND DISEASE DIAGNOSIS TO BOOST DEMAND
                    TABLE 55 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 56 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 57 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 58 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 59 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 60 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 61 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 62 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
    8.4 URINE 
           8.4.1 RAPID COMMERCIALIZATION OF URINE SAMPLE-BASED DIAGNOSTIC TESTS TO DRIVE MARKET
                    TABLE 63 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 64 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 65 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 66 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 67 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 68 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 69 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 70 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
    8.5 OTHER SAMPLES 
          TABLE 71 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022–2029 (USD MILLION)
          TABLE 72 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2030–2032 (USD MILLION)
          TABLE 73 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 74 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
          TABLE 75 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 76 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
          TABLE 77 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 78 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
 
9 EXOSOME THERAPEUTICS MARKET, BY APPLICATION (Page No. - 118)
    9.1 INTRODUCTION 
          TABLE 79 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
          TABLE 80 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
    9.2 CANCER 
           9.2.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET
                    TABLE 81 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 82 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 83 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 84 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 85 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 86 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 87 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 88 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
    9.3 DERMATOLOGICAL DISEASES 
           9.3.1 INCREASING R&D ACTIVITIES FOR WOUND HEALING AND REGENERATIVE MEDICINE TO DRIVE MARKET
                    TABLE 89 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 90 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 91 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 92 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 93 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 94 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 95 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 96 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
    9.4 MUSCULOSKELETAL DISORDERS 
           9.4.1 RISING INCIDENCE OF OSTEOARTHRITIS TO SUPPORT MARKET GROWTH
                    TABLE 97 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 98 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 99 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 100 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 101 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 102 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 103 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 104 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
    9.5 CARDIOVASCULAR DISEASES 
           9.5.1 GROWING FOCUS ON TARGETED THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH
                    TABLE 105 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 106 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 107 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 108 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 109 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 110 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 111 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 112 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
    9.6 OTHER APPLICATIONS 
          TABLE 113 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
          TABLE 114 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2030–2032 (USD MILLION)
          TABLE 115 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 116 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
          TABLE 117 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 118 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
          TABLE 119 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 120 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
 
10 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER (Page No. - 138)
     10.1 INTRODUCTION 
             TABLE 121 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             TABLE 122 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
     10.2 HOSPITALS 
             10.2.1 GROWING COLLABORATIONS WITH PHARMA & BIOPHARMA COMPANIES TO DRIVE MARKET
                        TABLE 123 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
                        TABLE 124 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2030–2032 (USD MILLION)
                        TABLE 125 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 126 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 127 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 128 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 129 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 130 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
     10.3 CLINICS AND PHYSICIAN SETTINGS 
             10.3.1 RISING ADOPTION OF LIQUID BIOPSY KITS TO SUPPORT MARKET GROWTH
                        TABLE 131 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2022–2029 (USD MILLION)
                        TABLE 132 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2030–2032 (USD MILLION)
                        TABLE 133 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 134 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 135 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 136 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 137 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 138 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
 
11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION (Page No. - 146)
     11.1 INTRODUCTION 
             TABLE 139 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
             TABLE 140 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
     11.2 NORTH AMERICA 
             11.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT
                        TABLE 141 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 142 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 143 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 144 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 145 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 146 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 147 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 148 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 149 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 150 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.2.2 US
                        11.2.2.1 Rising R&D initiatives for development of exosomes to drive market
                                      TABLE 151 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 152 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 153 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 154 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 155 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 156 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 157 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 158 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Increasing funding initiatives for genomic-based treatments to support market growth
                                      TABLE 159 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 160 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 161 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 162 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 163 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 164 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 165 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 166 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
     11.3 EUROPE 
             11.3.1 EUROPE: RECESSION IMPACT
                        FIGURE 38 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT
                        TABLE 167 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 168 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 169 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 170 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 171 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 172 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 173 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 174 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 175 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 176 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.2 GERMANY
                        11.3.2.1 Commercialization of pipeline candidates to propel market
                                      TABLE 177 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 178 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 179 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 180 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 181 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 182 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 183 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 184 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Rising growth in life sciences research to drive market
                                      TABLE 185 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 186 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 187 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 188 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 189 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 190 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 191 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 192 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.4 FRANCE
                        11.3.4.1 Presence of emerging players for exosome preparation to fuel market
                                      TABLE 193 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 194 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 195 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 196 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 197 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 198 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 199 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 200 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.5 ITALY
                        11.3.5.1 Rising growth in biotech sector to boost demand
                                      TABLE 201 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 202 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 203 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 204 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 205 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 206 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 207 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 208 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.6 SPAIN
                        11.3.6.1 Increasing initiatives for exosome research to support market growth
                                      TABLE 209 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 210 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 211 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 212 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 213 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 214 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 215 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 216 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.7 REST OF EUROPE
                        TABLE 217 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 218 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 219 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 220 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 221 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 222 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 223 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 224 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
     11.4 ASIA PACIFIC 
             11.4.1 ASIA PACIFIC: RECESSION IMPACT
                        TABLE 225 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 226 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 227 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 228 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 229 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 230 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 231 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 232 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 233 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 234 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Increasing healthcare expenditure to propel market
                                      TABLE 235 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 236 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 237 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 238 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 239 JAPAN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 240 JAPAN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 241 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 242 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.3 CHINA
                        11.4.3.1 Rising incidence of chronic diseases to drive market
                                      TABLE 243 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 244 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 245 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 246 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 247 CHINA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 248 CHINA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 249 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 250 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.4 INDIA
                        11.4.4.1 Increasing pool of start-ups and rising funding investments to fuel market
                                      TABLE 251 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 252 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 253 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 254 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 255 INDIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 256 INDIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 257 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 258 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.5 SOUTH KOREA
                        11.4.5.1 Rising developments by leading market players to boost demand
                                      TABLE 259 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 260 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 261 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 262 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 263 SOUTH KOREA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 264 SOUTH KOREA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 265 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 266 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.6 AUSTRALIA
                        11.4.6.1 Increasing adoption of novel therapeutics to support market growth
                                      TABLE 267 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 268 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 269 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 270 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 271 AUSTRALIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 272 AUSTRALIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 273 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 274 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.7 REST OF ASIA PACIFIC
                        TABLE 275 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 276 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 277 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 278 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 279 REST OF ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 280 REST OF ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 281 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 282 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
     11.5 REST OF THE WORLD 
             11.5.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET
                        TABLE 283 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 284 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 285 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 286 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 287 REST OF THE WORLD: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 288 REST OF THE WORLD: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 289 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 290 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.5.2 REST OF THE WORLD: RECESSION IMPACT
 
12 COMPETITIVE LANDSCAPE (Page No. - 205)
     12.1 OVERVIEW 
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             FIGURE 39 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS (2021−2024)
     12.3 REVENUE ANALYSIS 
             FIGURE 40 REVENUE ANALYSIS OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, 2022−2032
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 41 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SHARE ANALYSIS (2023)
             TABLE 291 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 42 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
             12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
                        12.5.5.1 Overall company footprint
                                      TABLE 292 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: OVERALL COMPANY FOOTPRINT
                        12.5.5.2 Regional footprint
                                      TABLE 293 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: REGIONAL FOOTPRINT
                        12.5.5.3 Product & service footprint
                                      TABLE 294 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PRODUCT & SERVICE FOOTPRINT
                        12.5.5.4 Type footprint
                                      TABLE 295 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: TYPE FOOTPRINT
                        12.5.5.5 Application footprint
                                      TABLE 296 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: APPLICATION FOOTPRINT
     12.6 COMPETITIVE EVALUATION MATRIX: START-UPS/SMES, 2023 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 DYNAMIC COMPANIES
             12.6.4 RESPONSIVE COMPANIES
                        FIGURE 43 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
             12.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
                        TABLE 297 EXOSOME THERAPEUTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
     12.7 COMPETITIVE SCENARIO 
             12.7.1 DEALS
                        TABLE 298 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DEALS, JANUARY 2021−APRIL 2024
             12.7.2 OTHER DEVELOPMENTS
                        TABLE 299 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021−APRIL 2024
 
13 COMPANY PROFILES (Page No. - 216)
(Business overview, Products/Solutions/Services offered, Recent developments & MnM View)*
     13.1 KEY PLAYERS 
             13.1.1 BIO-TECHNE
                        TABLE 300 BIO-TECHNE: COMPANY OVERVIEW
                        FIGURE 44 BIO-TECHNE: COMPANY SNAPSHOT (2023)
                        TABLE 301 BIO-TECHNE: PRODUCTS/SERVICES OFFERED
                        TABLE 302 BIO-TECHNE: DEALS
                        TABLE 303 BIO-TECHNE: OTHER DEVELOPMENTS
             13.1.2 NANOFCM INC.
                        TABLE 304 NANOFCM INC.: COMPANY OVERVIEW
                        TABLE 305 NANOFCM INC.: PRODUCTS/SERVICES OFFERED
             13.1.3 SYSTEM BIOSCIENCES, LLC.
                        TABLE 306 SYSTEM BIOSCIENCES, LLC.: COMPANY OVERVIEW
                        TABLE 307 SYSTEM BIOSCIENCES, LLC.: PRODUCTS/SERVICES OFFERED
             13.1.4 CAPITAL BIOSCIENCES, INC.
                        TABLE 308 CAPITAL BIOSCIENCES, INC.: COMPANY OVERVIEW
                        TABLE 309 CAPITAL BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED
             13.1.5 AMSBIO
                        TABLE 310 AMSBIO: COMPANY OVERVIEW
                        TABLE 311 AMSBIO: PRODUCTS/SERVICES OFFERED
             13.1.6 INOVIQ
                        TABLE 312 INOVIQ: COMPANY OVERVIEW
                        FIGURE 45 INOVIQ: COMPANY SNAPSHOT (2023)
                        TABLE 313 INOVIQ: PRODUCTS/SERVICES OFFERED
                        TABLE 314 INOVIQ: DEALS
             13.1.7 DIRECT BIOLOGICS LLC
                        TABLE 315 DIRECT BIOLOGICS: COMPANY OVERVIEW
                        TABLE 316 DIRECT BIOLOGICS: PRODUCTS/SERVICES OFFERED
                        TABLE 317 DIRECT BIOLOGICS: REGULATORY APPROVALS
                        TABLE 318 DIRECT BIOLOGICS: OTHER DEVELOPMENTS
             13.1.8 REGENEUS LTD
                        TABLE 319 REGENEUS LTD: COMPANY OVERVIEW
                        TABLE 320 REGENEUS LTD: PRODUCTS/SERVICES OFFERED
             13.1.9 CUREXSYS
                        TABLE 321 CUREXSYS: COMPANY OVERVIEW
                        TABLE 322 CUREXSYS: PRODUCTS/SERVICES OFFERED
             13.1.10 AEGLE THERAPEUTICS
                        TABLE 323 AEGLE THERAPEUTICS: COMPANY OVERVIEW
                        TABLE 324 AEGLE THERAPEUTICS: PRODUCTS/SERVICES OFFERED
*Details on Business overview, Products/Solutions/Services offered, Recent developments & MnM View might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS 
             13.2.1 MERCY BIOANALYTICS
                        TABLE 325 MERCY BIOANALYTICS: COMPANY OVERVIEW
             13.2.2 NANOSOMIX, INC.
                        TABLE 326 NANOSOMIX, INC.: COMPANY OVERVIEW
             13.2.3 EXONOX BIOSCIENCES, INC.
                        TABLE 327 EXONOX BIOSCIENCES, INC.: COMPANY OVERVIEW
             13.2.4 MULTIMMUNE GMBH
                        TABLE 328 MULTIMMUNE GMBH: COMPANY OVERVIEW
             13.2.5 CAPRICOR THERAPEUTICS, INC.
                        TABLE 329 CAPRICOR THERAPEUTICS, INC.: COMPANY OVERVIEW
             13.2.6 EVOX THERAPEUTICS
                        TABLE 330 EVOX THERAPEUTICS: COMPANY OVERVIEW
             13.2.7 ILIAS BIOLOGICS INC.
                        TABLE 331 ILIAS BIOLOGICS, INC.: COMPANY OVERVIEW
             13.2.8 RION
                        TABLE 332 RION: COMPANY OVERVIEW
             13.2.9 EXOGENUS THERAPEUTICS
                        TABLE 333 EXOGENUS THERAPEUTICS: COMPANY OVERVIEW
             13.2.10 EVERZOM
                        TABLE 334 EVERZOM: COMPANY OVERVIEW
             13.2.11 KIMERA LABS
                        TABLE 335 KIMERA LABS: COMPANY OVERVIEW
 
14 APPENDIX (Page No. - 244)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the exosome diagnostics and therapeutics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the exosome diagnostics and therapeutics market. The secondary sources referred to for this research study include publications from government sources, such as National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), World Health Organization (WHO), European Pharmaceutical Review, American Society of Gene & Cell Therapy (ASGCT), European Society of Gene and Cell Therapy (ESGCT), European Medicines Agency (EMA), and the Alliance for Regenerative Medicine (ARM). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global exosome diagnostics and therapeutics market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Exosome Diagnostics and Therapeutics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the exosome diagnostics and therapeutics market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the RNA therapeutics market and other dependent submarkets. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Exosome Diagnostics and Therapeutics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the RNA therapeutics industry.

Market Definition

Recent advancements in regenerative medicine have enabled researchers to extract exosomes from mesenchymal stem cells (MSCs), which possess remarkable regenerative capabilities for addressing diseases. Exosomes play a crucial role in diagnosing conditions, administering therapies, and modulating disease progression. Numerous in vitro investigations have demonstrated exosome safety, effectiveness, and therapeutic promise across various conditions, including cancer, neurodegenerative disorders, cardiovascular ailments, and orthopedic conditions. Moreover, exosomes have the potential to serve as diagnostic tools for early-stage disease detection, owing to their ability to transport protein biomarkers linked to specific diseases.

Stakeholders

  • Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Drug Discovery Companies
  • Venture Capitalists and Investors
  • Contract Development & Manufacturing Organizations
  • Government Associations
  • Healthcare Associations/Institutes
  • Business Research & Consulting Service Providers

Report Objectives

  • To define, describe, and forecast the exosome diagnostics and therapeutics market based on type, product & service, source, application, end-user, and region
  • To provide detailed information about the drivers, restraints, opportunities, and challenges influencing the market growth
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall exosome diagnostics and therapeutics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of market segments in North America, Europe, the Asia Pacific (APAC), and Rest of the World (ROW)
  • To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, product portfolios, and financials
  • To track and analyze competitive developments, such as partnerships, collaborations, agreements, and acquisitions, in the exosome diagnostics and therapeutics market
  • Micromarkets are the further segments and subsegments of the exosome diagnostics and therapeutics market.
  • Core competencies of companies are captured in terms of the key developments, market shares, and key strategies adopted to sustain their positions in the market.

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Company Information: Detailed analysis and profiling of additional market players (up to five)
  • Geographic Analysis:  Further breakdown of the Rest of the World (ROW), based on approvals and feasibility. Further breakdown of the Rest of Europe market, by country, based on approvals and feasibility. Further breakdown of the Rest of Asia Pacific market, by country, based on approvals and feasibility
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
BT 9039
Published ON
Jun, 2024
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Exosome Diagnostics and Therapeutics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback